Simulations Plus, Inc. (NASDAQ:SLP) has been given an average broker rating score of 2.00 (Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation.
Brokerages have set a 12-month consensus target price of $25.00 for the company and are predicting that the company will post $0.14 EPS for the current quarter, according to Zacks. Zacks has also assigned Simulations Plus an industry rank of 84 out of 256 based on the ratings given to its competitors.
SLP has been the topic of several research reports. BidaskClub upgraded Simulations Plus from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. ValuEngine upgraded Simulations Plus from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Zacks Investment Research upgraded Simulations Plus from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a research note on Saturday, May 11th.
Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Tuesday, April 9th. The technology company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.02. The business had revenue of $8.47 million for the quarter, compared to analyst estimates of $8.10 million. Simulations Plus had a return on equity of 22.87% and a net margin of 23.61%. Equities research analysts expect that Simulations Plus will post 0.44 earnings per share for the current year.
In other Simulations Plus news, Director David L. Ralph sold 3,000 shares of the business’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $22.74, for a total transaction of $68,220.00. Following the completion of the sale, the director now owns 18,006 shares of the company’s stock, valued at $409,456.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Walter S. Woltosz sold 18,500 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $22.11, for a total value of $409,035.00. Following the sale, the chairman now directly owns 5,196,039 shares of the company’s stock, valued at approximately $114,884,422.29. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $952,150 in the last ninety days. 31.57% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the business. Municipal Employees Retirement System of Michigan bought a new position in shares of Simulations Plus in the fourth quarter worth about $1,335,000. Martingale Asset Management L P boosted its stake in shares of Simulations Plus by 4.7% in the fourth quarter. Martingale Asset Management L P now owns 73,608 shares of the technology company’s stock worth $1,465,000 after acquiring an additional 3,300 shares during the period. Wasatch Advisors Inc. boosted its stake in shares of Simulations Plus by 15.6% in the first quarter. Wasatch Advisors Inc. now owns 343,122 shares of the technology company’s stock worth $7,243,000 after acquiring an additional 46,310 shares during the period. William Blair Investment Management LLC boosted its stake in shares of Simulations Plus by 8.8% in the first quarter. William Blair Investment Management LLC now owns 485,040 shares of the technology company’s stock worth $10,239,000 after acquiring an additional 39,114 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Simulations Plus by 6.5% in the fourth quarter. Geode Capital Management LLC now owns 128,181 shares of the technology company’s stock worth $2,550,000 after acquiring an additional 7,794 shares during the period. 41.28% of the stock is owned by institutional investors and hedge funds.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Article: Lock-Up Period Expiration
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.